GOG-3102/MK2870-021

Trial Overview

Official Title

A Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance with or without Bevacizumab versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy

Study Purpose

To test the safety of sac-TMT when given alone or with bevacizumab; to see how well sac-TMT +/- bevacizumab works compared to standard of care treatment; and to compare the quality of life of participants receiving the study treatment vs. standard of care treatment

Diagnosis

Newly diagnosed epithelial ovarian, fallopian tube, or peritoneal cancer, Stage III or IV

Eligibility

Currently receiving or just completed first-line platinum-based chemotherapy without disease progression, HRD/BRCA negative, surgically resected/debulked

Intervention

Arm 1: Sacituzumab Tirumotecan (sac-TMT) every 2 weeks +/- Bevacizumab every 3 weeks

Arm 2: Observation +/- Bevacizumab every 3 weeks

For more information, visit clinicaltrials.gov.

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
19 and older
Phase
Phase III
Methodist Health System Trial Code
NCT07181109
Related Specialties